title: Does atopy influence the effectiveness of treatment of adenoid hypertrophy with mometasone furoate?
abstract: BACKGROUND
  The effect of topical mometasone for adenoid hypertrophy treatment is well established. Nevertheless, the influence of atopy on this treatment remains ill defined.
  
  
  OBJECTIVE
  This study aims to compare the effects of topical mometasone furoate treatment on the adenoid tissue between atopic and nonatopic children.
  
  
  METHODS
  Fifty-one children with obstructive respiratory complaints underwent a semistructured clinical questionnaire on nasal symptoms, prick test, and nasoendoscopy. Nasoendoscopic images were digitalized, and both adenoid and nasopharyngeal areas were measured in pixels; the relative adenoid/nasopharyngeal area was calculated. Patients were initially treated for 40 days with nasal saline solution. In a subsequent 40-day period, topical mometasone furoate (total dose, 100 μg/day) was used.
  
  
  RESULTS
  Topical mometasone significantly improved nasal obstruction, snoring, and apnea and also significantly reduced the adenoid tissue area related to the nasopharynx (p < 0.0001). Treatment with this glucocorticoid was not influenced by atopy, neither for symptoms nor for adenoid area.
  
  
  CONCLUSIONS
  Topical mometasone furoate significantly reduced the adenoid tissue area and led to a supplementary improvement of nasal symptoms. This improvement was similar for atopic and nonatopic patients.
authors.affiliation: Department of Ophthalmology, Otorhinolaryngology, and Head and Neck Surgery, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
authors.forename: Renato M
authors.initials: RM
authors.lastname: Rezende
authors.forename: Flávia S
authors.initials: FS
authors.lastname: Amato
authors.forename: Aline P
authors.initials: AP
authors.lastname: Barbosa
authors.forename: Ulissis P
authors.initials: UP
authors.lastname: Menezes
authors.forename: Patrícia
authors.initials: P
authors.lastname: Rezende
authors.forename: Virgínia P L
authors.initials: VP
authors.lastname: Ferriani
authors.forename: Wilma T
authors.initials: WT
authors.lastname: Anselmo-Lima
authors.forename: Fabiana C P
authors.initials: FC
authors.lastname: Valera
mesh_terms: D000234:Adenoids / Q000473:pathology*; D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D006984:Hypertrophy; D008297:Male; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate